Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;32(1):588-599.
doi: 10.1080/14756366.2017.1279156.

New arylsparteine derivatives as positive inotropic drugs

Affiliations

New arylsparteine derivatives as positive inotropic drugs

Vito Boido et al. J Enzyme Inhib Med Chem. 2017 Dec.

Abstract

Positive inotropic agents are fundamental in the treatment of heart failure; however, their arrhythmogenic liability and the increased myocardial oxygen demand strongly limit their therapeutic utility. Pursuing our study on cardiovascular activities of lupin alkaloid derivatives, several 2-(4-substituted-phenyl)-2-dehydrosparteines and 2-(4-substituted-phenyl)sparteines were prepared and tested for inotropic and chronotropic activities on isolated guinea pig atria. Four compounds (6b, 6e, 7b, and 7f) exhibited significant inotropism that, at the higher concentrations, was followed by negative inotropism or toxicity. Compound 7e (2-(4-tolyl)sparteine) exhibited a steep dose-depending inotropic activity up to the highest concentration tested (300 µM) with an Emax of 116.5 ± 3.4% of basal force, proving less potent but much more active in comparison to the highest concentrations tested of digoxin and milrinone having Emax of 87.5 ± 3.1% and 52.2 ± 1.1%, respectively. Finally, docking studies suggested that the relevant sparteine derivatives could target the sigma-1 receptor, whose involvement in cardiac activity is well documented.

Keywords: 2-aryl-2-dehydrosparteines; 2-arylsparteines; Lupin alkaloids; positive inotropic agents.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Lupin alkaloids and derivatives investigated as inotropic agents.
Figure 2.
Figure 2.
Inotropic effects of digoxin, milrinone and compound 7e. *p < 0.05 compound 7e versus milrinone.
Scheme 1:
Scheme 1:
Reagents and conditions: (a) dry Et2O; reflux, 2 h; (b) dil. HCl; (c) H2/Pd-C, EtOH, r.t.; (d) NaBH4, EtOH; reflux, 4 h. *(±)-lupanine, for the sake of simplicity, only one enantiomer is shown.
Figure 3.
Figure 3.
Chronotropic effects of digoxin, milrinone and compound 7e. *p < 0.05 compound 7e versus milrinone.
Figure 4.
Figure 4.
Inotropic cytisine derivatives.
Figure 5.
Figure 5.
Some arylalkyl amines with high affinity for sigma-1 receptor.
Figure 6.
Figure 6.
X-ray crystallographic data of the human sigma-1 receptor and of the ligand PD144418. The most important residues are labeled and colored in orange.
Figure 7.
Figure 7.
Docking mode of 7b and of 7e within the X-ray crystallographic data of the human sigma-1 receptor and of the ligand PD144418 (C atom; brown). The most important residues are labeled.

Similar articles

Cited by

References

    1. Dickstein K, Cohen-Solal A, Filippatos G, et al. . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–442. - PubMed
    1. Feldman AM.Classification of positive inotropic agents. J Am Coll Cardiol 1993;22:1223–7. - PubMed
    1. Francis GS, Bartos JA, Adatya S.. Inotropes. J Am Coll Cardiol 2014;63:2069–78. - PubMed
    1. Tariq S, Aronow WS.. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci 2015;16:29060–8. - PMC - PubMed
    1. Endoh M, Hori M.. Basic pharmacology and clinical application of new positive inotropic agents. Drugs Today 1993;29:29–54.

LinkOut - more resources